Aselizumab
Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.[1]
References
- ↑ Seekamp, A; Van Griensven, M; Dhondt, E; Diefenbeck, M; Demeyer, I; Vundelinckx, G; Haas, N; Schaechinger, U et al. (2004). "The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial". Critical Care Medicine 32 (10): 2021–8. doi:10.1097/01.CCM.0000142396.59236.F3. PMID 15483410.
|
---|
| Intracellular (initiation) | |
---|
| Intracellular (reception) | |
---|
| Extracellular | |
---|
| |
---|
| Description |
- Physiology
- cells
- autoantigens
- autoantibodies
- complement
- surface antigens
- IG receptors
|
---|
| Disease |
- Allergies
- Immunodeficiency
- Immunoproliferative immunoglobulin disorders
- Hypersensitivity and autoimmune disorders
- Neoplasms and cancer
|
---|
| Treatment |
- Procedures
- Drugs
- antihistamines
- immunostimulants
- immunosuppressants
- monoclonal antibodies
|
---|
|
|
|
---|
| Immune system ("-l(i[m])-") | Human ("-limu-") | |
---|
| Mouse ("-limo-") | |
---|
| Chimeric ("-lixi-") | |
---|
| Humanized ("-lizu-") | |
---|
| Chimeric + humanized ("-lixizu-") | |
---|
|
---|
| Interleukin ("-k(i[n])-") | Human ("-kinu-") | |
---|
| Humanized ("-kizu-", "-kinzu-") | |
---|
|
---|
| Inflammatory lesions ("-les-") | |
---|
| |
---|
| Description |
- Physiology
- cells
- autoantigens
- autoantibodies
- complement
- surface antigens
- IG receptors
|
---|
| Disease |
- Allergies
- Immunodeficiency
- Immunoproliferative immunoglobulin disorders
- Hypersensitivity and autoimmune disorders
- Neoplasms and cancer
|
---|
| Treatment |
- Procedures
- Drugs
- antihistamines
- immunostimulants
- immunosuppressants
- monoclonal antibodies
|
---|
|
|